Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease

Movement Disorders

Volumn 19, Issue 5, 2004, Pages 571-579

  Abdo, W Farid ^a   de Jong, Daniëlle ^a   Hendriks, Jan C M ^a   Horstink, Martin W I M ^a   Kremer, Berry P H ^a   Bloem, Bastiaan R ^a   Verbeek, Marcel M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Brain specific proteins; Cerebrospinal fluid; Multiple system atrophy; Neurotransmitters; Parkinson's disease

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; ALBUMIN; GLIAL FIBRILLARY ACIDIC PROTEIN; HOMOVANILLIC ACID; LACTIC ACID; MYELIN BASIC PROTEIN; NEURON SPECIFIC ENOLASE; PYRUVIC ACID; TAU PROTEIN; 3 IODO 2 HYDROXY 6 METHOXY N ((1 ETHYL 2 PYRROLIDINYL)METHYL)BENZAMIDE; 3-IODO-2-HYDROXY-6-METHOXY-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)BENZAMIDE; BENZAMIDE DERIVATIVE; DIAGNOSTIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE; PYRROLIDINE DERIVATIVE; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEGENERATIVE DISEASE; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FEMALE; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME; BRAIN; CEREBROSPINAL FLUID; COMPUTER ASSISTED TOMOGRAPHY; ELECTROMYOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; METABOLISM; RADIOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; AGED; BENZAMIDES; BRAIN; DIAGNOSIS, DIFFERENTIAL; ELECTROMYOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HOMOVANILLIC ACID; HUMANS; HYDROXYINDOLEACETIC ACID; IODINE RADIOISOTOPES; LACTIC ACID; MALE; METHOXYHYDROXYPHENYLGLYCOL; MULTIPLE SYSTEM ATROPHY; NAD; PARKINSON DISEASE; PYRROLIDINES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 4544317796     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10714     Document Type: Article

References (33)

1. Quinn N. Multiple system atrophy - the nature of the beast. J Neurol Neurosurg Psychiatry 1989;(Suppl.):78-89.
2. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999;163:94-98.
3. Wenning GK, Ben-Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry 1995;58:160-166.
4. Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994;117:835-845.
5. Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 1997;12:133-147.
6. Fearnley JM, Lees AJ. Striatonigral degeneration. A clinicopathological study. Brain 1990;113:1823-1842.
7. Gouider-Khouja N, Vidailhet M, Bonnet AM, Pichon J, Agid Y. "Pure" striatonigral degeneration and Parkinson's disease: a comparative clinical study. Mov Disord 1995;10:288-294.
8. Gilman S, Quinn NP. The relationship of multiple system atrophy to sporadic olivopontocerebellar atrophy and odor forms of idiopathic late-onset cerebellar atrophy. Neurology 1996;46:1197-1199.
9. Wenning GK, Ben-Shlomo Y, Hughes A, Daniel SE, Lees A, Quinn NP. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? J Neurol Neurosurg Psychiatry 2000;68:434-440.
10. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001;57: 1497-1499.
11. Litvan I, Goetz CG, Jankovic J, et al. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol 1997;54:937-944.
12. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism - a prospective study. Can J Neurol Sci 1991;18: 275-278.
13. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
14. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861-870.
15. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992;42:1142-1146.
16. van Geel WJA, de Reus HPM, Nijzing H, Verbeek MM, Vos PE, Lamers KJ. Measurement of glial fibrillary acidic protein in blood: an analytical method. Clin Chim Acta 2002;326:151-154.
17. Herrmann M, Vos P, Wunderlich MT, de-Bruijn CH, Lamers KJ. Release of glial tissue-specific proteins after acute stroke: a comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke 2000;31:2670-2677.
18. Brautigam C, Wevers RA, Jansen RJ, Smeitink JA, de Rijk-van Andel JF, Gabreels FJ, Hoffmann GF. Biochemical hallmarks of tyrosine hydroxylase deficiency. Clin Chem 1998;44:1897-1904.
19. Chia LG, Cheng FC, Kuo JS. Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease. J Neurol Sci 1993;116:125-134.
20. Mann JJ, Stanley M, Kaplan RD, Sweeney J, Neophytides A. Central catecholamine metabolism in vivo and the cognitive and motor deficits in Parkinson's disease. J Neurol Neurosurg Psychiatry 1983;46:905-910.
21. Polinsky RJ, Brown RT, Burns RS, Harvey-White J, Kopin IJ. Low lumbar CSF levels of homovanillic acid and 5-hydroxyin-doleacetic acid in multiple system atrophy with autonomic failure. J Neurol Neurosurg Psychiatry 1988;51:914-919.
22. Mathias CJ, Williams AC. The Shy-Drager syndrome (and multiple system atrophy). In: Calne DB, editor. Neurodegenerative diseases. Philadelphia: WB Saunders; 1994. p 743-767.
23. Polinsky RJ, Jimerson DC, Kopin IJ. Chronic autonomic failure: CSF and plasma 3-methoxy-4-hydroxyphenylglycol. Neurology 1984;34:979-983.
24. Matsuo A, Akiguchi I, Lee GC, McGeer EG, McGeer PL, Kimura J. Myelin degeneration in multiple system atrophy detected by unique antibodies. Am J Pathol 1998;153:735-744.
25. Goedert M, Spillantini MG, Serpell LC, Berriman J, Smith MJ, Jakes R, Crowther RA. From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases. Philos Trans R Soc Lond B Biol Sci 2001;356:213-227.
26. Sjogren M, Davidsson P, Tullberg M, et al. Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001;70:624-630.
27. Vanmechelen E, Vanderstichele H, Davidsson P, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49-52.
28. Molina JA, Benito-Leon J, Jimenez-Jimenez FJ, et al. Tau protein concentrations in cerebrospinal fluid of non-demented Parkinson's disease patients. Neurosci Lett 1997;238:139-141.
29. Verbeek MM, de Jong D, Kremer HPH. Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases. Ann Clin Biochem 2003;40:25-40.
30. Sjogren M, Vanderstichele H, Agren H, et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 2001;47:1776-1781.
31. Holmberg B, Johnels B, Blennow K, Rosengren L. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord 2003;18:186-190.
32. Verbeek MM, Abdo WF, de Jong D, Horstink MWIM, Kremer HPH, Bloem BR. Cerebrospinal fluid Aβ42 levels in multiple system atrophy. Mov Disord 2004;DOI 10.1002/mds.10687.
33. Holmberg B, Rosengren L, Karlsson JE, Johnels B. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease. Mov Disord 1998;13:70-77.